Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
8.200
Open
8.200
VWAP
7.56
Vol
294.18K
Mkt Cap
172.45M
Low
7.340
Amount
2.23M
EV/EBITDA(TTM)
--
Total Shares
19.78M
EV
167.74M
EV/OCF(TTM)
--
P/S(TTM)
3.39K
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03) Mild Alzheimer's disease, Mild Cognitive Impairment and treatment-resistant depression (XPro). The NK Cell Priming Platform includes INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients with cancer. Its product platforms utilize a precision medicine approach for the treatment of hematologic and solid tumor malignancies, and chronic inflammation.
Show More
5 Analyst Rating
214.94% Upside
Wall Street analysts forecast INMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INMB is 23.40 USD with a low forecast of 20.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
214.94% Upside
Current: 7.430
Low
20.00
Averages
23.40
High
30.00
214.94% Upside
Current: 7.430
Low
20.00
Averages
23.40
High
30.00
Maxim Group
Jason McCarthy
Strong Buy
Maintains
$22 → $30
2025-02-13
Reason
Maxim Group
Jason McCarthy
Price Target
$22 → $30
2025-02-13
Maintains
Strong Buy
Reason
Scotiabank
George Farmer
Buy
Maintains
$22 → $23
2025-02-11
Reason
Scotiabank
George Farmer
Price Target
$22 → $23
2025-02-11
Maintains
Buy
Reason
Scotiabank raised the firm's price target on INmune Bio to $23 from $22 and keeps an Outperform rating on the shares. The company's management appears confident a Biologics License Application that will be filed with the FDA around the end of the year will be received positively, the analyst tells investors. Additionally, the firm believes a positive outcome of the XPRo Phase 2 trial is expected to read out in June, which would "completely dwarf" the CORDStrom commercial opportunity.
Alliance Global Partners
James Molloy
Strong Buy
Initiates
$20
2024-10-21
Reason
Alliance Global Partners
James Molloy
Price Target
$20
2024-10-21
Initiates
Strong Buy
Reason
Alliance Global Partners analyst James Molloy initiated coverage of INmune Bio with a Buy rating and $20 price target. INmune is developing a pipeline with two main assets: XPro, a tumor necrosis factor inhibitor that is being tested in early Alzheimer's Disease in a Phase 2 trial, and INKmune, a cell therapy that activates endogenous resting natural killer, or NK, cells in the tumor microenvironment to fight cancer using a patient's immune system, which is being studied in a Phase 1/2 clinical trial where it is in the Phase 1 dose escalation portion. The firm values the stock on a sum-of-the-parts basis with XPro for AD valued at $14 per share, and INKmune for mCRPC valued at $4 per share plus net cash at $2 per share adding up to its $20 per share price target.
Scotiabank
George Farmer
Buy
Initiates
$22
2024-08-22
Reason
Scotiabank
George Farmer
Price Target
$22
2024-08-22
Initiates
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for INmune Bio Inc (INMB.O) is -5.17, compared to its 5-year average forward P/E of -5.44. For a more detailed relative valuation and DCF analysis to assess INmune Bio Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-5.44
Current PE
-5.17
Overvalued PE
-2.96
Undervalued PE
-7.92
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
2321.74
Current PS
53.40
Overvalued PS
7597.24
Undervalued PS
-2953.76
Financials
Annual
Quarterly
FY2025Q1
YoY :
+257.14%
50.00K
Total Revenue
FY2025Q1
YoY :
-10.09%
-9.91M
Operating Profit
FY2025Q1
YoY :
-100.00%
N/A
Net Income after Tax
FY2025Q1
YoY :
-29.51%
-0.43
EPS - Diluted
FY2025Q1
N/A
Free Cash Flow
FY2025Q1
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
YoY :
-75.27%
-19.48K
Net Margin - %
Trading Trends
Insider
Insiders areBuying! The selling amount has increased 450.04% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
3
199.9K
USD
Months
0-12
1
36.4K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areBuying! The selling amount has increased 450.04% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
3
199.9K
USD
Months
0-12
1
36.4K
USD
Months
INMB News & Events
Events Timeline
2025-04-16 (ET)
2025-04-16
07:06:48
INmune Bio receives favorable patentability opinion for CORDStrom platform
2025-04-14 (ET)
2025-04-14
08:12:14
INmune Bio partners with Cell, Gene Therapy Catapult to scale up CORDStrom
2025-02-12 (ET)
2025-02-12
06:15:45
INmune Bio opens Phase II in high dose cohort of INKmune trial
Sign Up For More Events
Sign Up For More Events
News
9.5
05-05NewsfilterINmune Bio Inc. to Report First Quarter 2025 Financial Results and Provide Corporate Update on Thursday, May 8th
9.5
04-22BenzingaWhy Calix Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
7.5
04-14SeekingAlphaINmune Bio Partners with Cell and Gene Therapy Catapult
Sign Up For More News
People Also Watch
TSLA
Tesla Inc
347.680
USD
+4.07%
AAPL
Apple Inc
212.330
USD
-0.28%
META
Meta Platforms Inc
659.360
USD
+0.51%
ORCL
Oracle Corp
162.950
USD
+0.42%
MSFT
Microsoft Corp
452.940
USD
+0.85%
WMT
Walmart Inc
96.830
USD
+0.99%
AVGO
Broadcom Inc
232.120
USD
-0.13%
NVDA
NVIDIA Corp
135.340
USD
+4.16%
XOM
Exxon Mobil Corp
108.480
USD
-0.90%
AMZN
Amazon.com Inc
210.250
USD
-0.53%
FAQ
What is INmune Bio Inc (INMB) stock price today?
The current price of INMB is 7.43 USD — it has decreased -7.82 % in the last trading day.
What is INmune Bio Inc (INMB)'s business?
What is the price predicton of INMB Stock?
What is INmune Bio Inc (INMB)'s revenue for the last quarter?
What is INmune Bio Inc (INMB)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for INmune Bio Inc (INMB)'s fundamentals?
How many employees does INmune Bio Inc (INMB). have?